Business Wire

ETA

19.5.2023 18:55:34 CEST | Business Wire | Press release

Share
Egypt: A Family-Friendly Exotic Destination

If you are planning a family holiday, look no further than Egypt. The country is renowned for its all-inclusive hotels and resorts that cater to the needs of families with children. These resorts offer entertainment programs and excursions suitable for all age groups. Museums and cultural sights also offer family-friendly activities. Furthermore, Egypt's warm temperatures and dry climate throughout the year make it an ideal destination for holidays all year round, with sandy beaches and shallow water that are sure to excite children.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230519005234/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Family Holiday in Egypt (Photo: Business Wire)

What Makes a Holiday Family-Friendly?

A holiday is meant to be a time for relaxation, escaping everyday life and enjoying oneself. However, this can be challenging when traveling with children. Egypt's all-inclusive hotels and resorts provide stress-free options for families with children. The resorts offer animation programs for children of different ages, with pools featuring water slides and children's pools. In addition, multilingual caretakers are available to look after children when parents want to pursue their own plans undisturbed for an afternoon or evening. This allows parents to relax and enjoy their holiday with peace of mind.

Activities for the whole Family

There are many activities that families can enjoy together in Egypt. Clubs and resorts offer a range of sports activities, including mini golf, beach football, and volleyball. For those interested in water activities like diving, snorkelling, or kite surfing, there are beginner courses as well as special children's courses available.

In the cities itself, families can find a variety of activities like water parks, amusement parks, safari tours, and aquariums. Additionally, museums can be a great way to make history exciting for children, with the Egyptian Museum in Cairo offering guided tours specifically designed for kids. Outside of the cities, families can have adventures like desert tours in buggies or riding on camels. Compared to similar activities in Europe, leisure activities in Egypt are much more affordable, allowing families to experience more together or take some time for themselves to relax.

"Nile Trips and Abu Simbel"

Aswan, the southernmost city in Egypt, is located directly on the Nile, making it an excellent starting point for interesting and varied tours. Visitors can take Nile trips to the temples of Kom Ombo and even further north to Luxor. Close to the city lies Lake Nasser, at the southern end of which stands the spectacular temple complex of Abu Simbel. The four 20-metre-high statues of Pharaoh Ramses II at the main entrance of the temple are an incomparable sight and rightly rank among the most popular sights in the country.

Aswan itself is also full of treasures to discover, such as the Agha Khan Mausoleum on the west bank of the Nile, or the archaeological Nubian Museum that highlights the history of the Nubian population, who make up a large part of Aswan's inhabitants. The city also includes numerous islands in the Nile, such as Elephantine Island, or Kitchener Island to the north, where the city's botanical garden can be found.

Background information on the Egyptian Tourism Authority
The Egyptian Tourism Authority (ETA) was established in 1981 to boost international tourism by highlighting Egypt's long history and traditional civilization and promoting the country and its many tourist attractions. ETA's mission also includes promoting domestic tourism, raising awareness of tourism throughout the country, and strengthening the connection between Egyptians and their heritage.

The ETA's focus is on the one hand on the diversity of attractions and destinations within Egypt, and on the other hand on developing marketing strategies and programs to promote tourism, as well as providing technical and marketing support. It also organizes and sponsors tourism, sports, and social and cultural events throughout the country. The ETA Board of Directors is chaired by the Minister of Tourism.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005234/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release

One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye